Yuichiro Shindo1, Jacquelyn S McDonough2, Katherine C Chang2, Murali Ramachandra3, Pottayil G Sasikumar3, Richard S Hotchkiss4. 1. Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri; Department of Respiratory Medicine, Institute for Advanced Research, Nagoya University, Nagoya, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. 2. Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri. 3. Aurigene Discovery Technologies Limited, Bangalore, Karnataka, India. 4. Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; Department of Surgery, Washington University School of Medicine, St. Louis, Missouri; Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: hotch@anest.wustl.edu.
Abstract
BACKGROUND: Sepsis remains a leading cause of death in most intensive care units. Many deaths in sepsis are due to nosocomial infections in patients who have entered the immunosuppressive phase of the disorder. One cause of immunosuppression in sepsis is T-cell exhaustion mediated by programmed cell death-1 (PD-1) interaction with its ligand (PD-L1). Studies demonstrated that blocking the interaction of PD-1 with PD-L1 with knockout mice or inhibitory antibodies reversed T-cell dysfunction and improved sepsis survival. This study assessed the efficacy of a novel short-acting peptide (compound 8) that inhibits PD-1:PD-L1 signaling in a clinically relevant second-hit fungal sepsis model. METHODS: Mice underwent cecal ligation and puncture to induce peritonitis. Three days later, mice received intravenous injection of Candida albicans. Forty-eight hours after Candida infection, mice were treated with compound 8 or inactive peptide. The effect of Candida infection on expression of coinhibitory molecules, PD-1, and PD-L1 were quantitated by flow cytometry on CD4+ cells, CD8+ cells, natural killer (NK) cells, and natural killer T-cells (NKT). The effect of compound 8 on survival was also examined. RESULTS: Four days after fungal infection, PD-1 and PD-L1 expressions were markedly increased on CD4+, NK, and NKT cells in septic versus sham-operated mice (%PD-1 on CD4+, 11.9% versus 2.8%; and %PD-L1 on NKT, 14.8% versus 0.5%). Compared with control, compound 8 caused a 2-fold increase in survival from 30% to 60%, P < 0.05. CONCLUSIONS: Compound 8 significantly improved survival in a clinically relevant immunosuppressive model of sepsis. These results support immunoadjuvant therapy targeting T-cell exhaustion in this lethal disease.
BACKGROUND:Sepsis remains a leading cause of death in most intensive care units. Many deaths in sepsis are due to nosocomial infections in patients who have entered the immunosuppressive phase of the disorder. One cause of immunosuppression in sepsis is T-cell exhaustion mediated by programmed cell death-1 (PD-1) interaction with its ligand (PD-L1). Studies demonstrated that blocking the interaction of PD-1 with PD-L1 with knockout mice or inhibitory antibodies reversed T-cell dysfunction and improved sepsis survival. This study assessed the efficacy of a novel short-acting peptide (compound 8) that inhibits PD-1:PD-L1 signaling in a clinically relevant second-hit fungal sepsis model. METHODS:Mice underwent cecal ligation and puncture to induce peritonitis. Three days later, mice received intravenous injection of Candida albicans. Forty-eight hours after Candida infection, mice were treated with compound 8 or inactive peptide. The effect of Candida infection on expression of coinhibitory molecules, PD-1, and PD-L1 were quantitated by flow cytometry on CD4+ cells, CD8+ cells, natural killer (NK) cells, and natural killer T-cells (NKT). The effect of compound 8 on survival was also examined. RESULTS: Four days after fungal infection, PD-1 and PD-L1 expressions were markedly increased on CD4+, NK, and NKT cells in septic versus sham-operated mice (%PD-1 on CD4+, 11.9% versus 2.8%; and %PD-L1 on NKT, 14.8% versus 0.5%). Compared with control, compound 8 caused a 2-fold increase in survival from 30% to 60%, P < 0.05. CONCLUSIONS: Compound 8 significantly improved survival in a clinically relevant immunosuppressive model of sepsis. These results support immunoadjuvant therapy targeting T-cell exhaustion in this lethal disease.
Authors: R S Hotchkiss; K W Tinsley; P E Swanson; R E Schmieg; J J Hui; K C Chang; D F Osborne; B D Freeman; J P Cobb; T G Buchman; I E Karl Journal: J Immunol Date: 2001-06-01 Impact factor: 5.422
Authors: Christopher G Davis; Kathy Chang; Dale Osborne; Andrew H Walton; W Michael Dunne; Jared T Muenzer Journal: Biochem Biophys Res Commun Date: 2011-09-12 Impact factor: 3.575
Authors: Pavan Brahmamdam; Shigeaki Inoue; Jacqueline Unsinger; Katherine C Chang; Jonathan E McDunn; Richard S Hotchkiss Journal: J Leukoc Biol Date: 2010-05-18 Impact factor: 4.962
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Golnaz Kamalinia; Brian J Engel; Anupallavi Srinivasamani; Brian J Grindel; Justin N Ong; Michael A Curran; Terry T Takahashi; Steven W Millward; Richard W Roberts Journal: ACS Chem Biol Date: 2020-04-30 Impact factor: 5.100
Authors: John D Lyons; Ching-Wen Chen; Zhe Liang; Wenxiao Zhang; Deena B Chihade; Eileen M Burd; Alton B Farris; Mandy L Ford; Craig M Coopersmith Journal: Shock Date: 2019-06 Impact factor: 3.454
Authors: Timothy E Sweeney; Tej D Azad; Michele Donato; Winston A Haynes; Thanneer M Perumal; Ricardo Henao; Jesús F Bermejo-Martin; Raquel Almansa; Eduardo Tamayo; Judith A Howrylak; Augustine Choi; Grant P Parnell; Benjamin Tang; Marshall Nichols; Christopher W Woods; Geoffrey S Ginsburg; Stephen F Kingsmore; Larsson Omberg; Lara M Mangravite; Hector R Wong; Ephraim L Tsalik; Raymond J Langley; Purvesh Khatri Journal: Crit Care Med Date: 2018-06 Impact factor: 7.598
Authors: Koichiro Sueyoshi; Carola Ledderose; Yong Shen; Albert H Lee; Nathan I Shapiro; Wolfgang G Junger Journal: J Biol Chem Date: 2019-02-20 Impact factor: 5.157
Authors: Eleanor A Fallon; Bethany M Biron-Girard; Chun-Shiang Chung; Joanne Lomas-Neira; Daithi S Heffernan; Sean F Monaghan; Alfred Ayala Journal: J Leukoc Biol Date: 2018-02-02 Impact factor: 4.962
Authors: Scott C Brakenridge; Philip A Efron; Julie A Stortz; Teczan Ozrazgat-Baslanti; Gabriela Ghita; Zhongkai Wang; Azra Bihorac; Alicia M Mohr; Babette A Brumback; Lyle L Moldawer; Frederick A Moore Journal: J Trauma Acute Care Surg Date: 2018-08 Impact factor: 3.313
Authors: Isaac J Jensen; Patrick W McGonagill; Noah S Butler; John T Harty; Thomas S Griffith; Vladimir P Badovinac Journal: J Immunol Date: 2021-01-29 Impact factor: 5.422